Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:57 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 24 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Insulin drip Clear all

Conditions: Coronary Artery Disease
Interventions: Sitagliptin, Placebo, Regular Human Insulin, Insulin glargine, Supplemental insulin (Insulin lispro), Supplemental insulin (Insulin aspart); Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 4
States / cities: Atlanta, Georgia

Conditions: Open Angle Glaucoma, Primary Open Angle Glaucoma, Low Tension Glaucoma, Pigmentary Glaucoma, Pseudoexfoliation Glaucoma
Interventions: EYED-002 Low Dose (721 U/mL topical insulin), EYED-002 High Dose (1442 U/mL topical insulin), EYED-002 (highest tolerated dose, 12-month), Vehicle Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Hypoglycemia
Interventions: Continuous Glucose Monitoring, activity monitor, Mixed meal tolerance test, Glucagon Sensitivity Testing, Hypoglycemic Hyperinsulinemic Clamp, analysis of fecal microbiome; Diagnostic Test
Lead sponsor: Joslin Diabetes Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetes Mellitus, Type 2 Diabetes Mellitus, Adult-Onset Diabetes Mellitus, Non-Insulin-Dependent Diabetes Mellitus, Noninsulin Dependent Diabetes Mellitus, Type II
Interventions: High Frequency Financial Incentive, Moderate Frequency Financial Incentive, Low Frequency Financial Incentive; Behavioral
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 21 Years to 100 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Hypertension, Cardiovascular Diseases
Interventions: Ascorbic acid solution (American Regent Laboratories Inc.), Saline; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 35 Years to 65 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Diabetes, Pregnancy
Interventions: Insulin drip; Procedure
Lead sponsor: WellSpan Health; Other
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: York, Pennsylvania

Conditions: Type 1 Diabetes, Type 2 Diabetes
Interventions: Not listed
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Type 1 Diabetes
Interventions: Autologous UCB, Omega 3 FA, Vitamin D; Biological · Dietary Supplement
Lead sponsor: University of Florida; Other
Eligibility: 1 Year to 18 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Diabetes
Interventions: Glargine; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 19 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Diabetes Mellitus, Type 2
Interventions: Afrezza plus One Drop | Premium, One Drop | Premium; Drug · Other
Lead sponsor: Informed Data Systems, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Gestational Diabetes Mellitus in Pregnancy, Pregestational Diabetes Mellitus, Neonatal Hypoglycemia
Interventions: Standard Intrapartum Glucose Target Range, Liberalized Intrapartum Glucose Target Range; Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: Female only
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Glaucoma
Interventions: Insulin, 4 units, Insulin, 20 units, insulin, 4 units twice daily, insulin, 20 units twice daily, insulin, 4 units three times daily, insulin, 20 units three times daily; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Glycemic Control
Interventions: A IV Insulin drip, B Low Dose GIK, C High Dose GIK; Drug
Lead sponsor: American Heart Association; Other
Eligibility: 18 Years to 90 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hyperglycemia, Diabetes
Interventions: insulin glargine; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Diabetic Ketoacidosis
Interventions: Insulin Glargine, Regular Insulin; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Gestational Diabetes, Pregestational Diabetes
Interventions: Usual Care, Permissive intrapartum glucose control; Procedure
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older · Female only
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hyperglycemia
Interventions: Glucommander-Guided Intravenous Insulin Infusion, Standard Intravenous Insulin Infusion, Simple Calculated Intravenous Insulin Infusion; Procedure
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years to 80 Years
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 3
States / cities: Chicago Heights, Illinois • Albuquerque, New Mexico

Conditions: Diabetes, End Stage Renal Disease
Interventions: Insulin, Insulin, Asp(B28)-; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Diabetes Mellitus, Diabetic Ketoacidosis
Interventions: Early feeding with an oral diet; Other
Lead sponsor: Texas Tech University Health Sciences Center; Other
Eligibility: 18 Years to 89 Years
Enrollment: 93 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Lubbock, Texas

Conditions: Glycemic Control
Interventions: IV Insulin drip, Insulin; Drug
Lead sponsor: American Heart Association; Other
Eligibility: 18 Years to 90 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Acute Ischemic Stroke, Diabetes, Hyperglycemia
Interventions: IV insulin to maintain target glucose concentration of 80-130 mg/dL, Standard Care control - sliding scale insulin to keep glucose less than 180 mg/dL; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 1,151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 70
States / cities: Tucson, Arizona • Long Beach, California • Los Angeles, California + 45 more

Conditions: Hyperglycemia
Interventions: Insulin Drip Therapy; Drug
Lead sponsor: Emory University; Other
Eligibility: 19 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Diabetes
Interventions: Detemir; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 19 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Interventions: 3 hours humulin R 100 IU/mL PIT, 2 hours humulin R 100 IU/mL PIT; Drug
Lead sponsor: Sciema UG; Other
Eligibility: 18 Years to 99 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Sitagliptin in Non-Diabetic Patients Undergoing Cardiac Surgery

Topical Insulin for Glaucoma (TING2)

Mechanisms of Post-Bariatric Hypoglycemia

Financial Incentives Telephone Education and Skills Trial in African Americans With Diabetes (FITEST)

Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)

A Comparison of Insulin Drip Protocols in Labor: A Randomized Trial

Accuracy Comparison of Two CGMs in Hospitalized Patients

Cord Blood Plus Vitamin D and Omega 3s in T1D

Effectiveness of Adding Subcutaneous Long-acting Glargine to Insulin Drip Therapy Compared With Standard Insulin Drip Therapy

A Randomized Controlled Trial Evaluating One Drop | Premium With Afrezza vs. One Drop | Premium Alone

Intrapartum Glucose Control and Risk of Neonatal Hypoglycemia

Topical Insulin for Glaucoma

Improving Outcomes In Diabetic Patients During CABG Surgery By Optimizing Glycemic Control

Conversion of Hyperglycemic Patients Being Treated With Intravenous Insulin Infusions to Lantus Insulin

Effectiveness of Subcutaneous Glargine On The Time To Closure of The Anion Gap in Patients Presenting to the Emergency Department With Diabetic Keto-acidosis

Permissive Intrapartum Glucose Control

Comparative Trial Between 3 Types of Insulin Infusion Protocols

Hyperglycemia in Renal Transplantation

Starvation in the Treatment of Diabetic Ketoacidosis

Aggressive Versus Moderate Glycemic Control in Diabetic Coronary Bypass Patients

Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial

Insulin Infusion in the Hospital Wards

Effectiveness of Adding Subcutaneous Long-Acting Detemir to Insulin Drip Therapy Compared With Standard Insulin Drip Therapy

Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus